Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study.

@article{Asthana1999CognitiveAN,
  title={Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study.},
  author={Sanjay Asthana and Suzanne Craft and Laura D. Baker and Murray A. Raskind and Roger S. Birnbaum and Cassin Lofgreen and Richard C. Veith and Stephen R. Plymate},
  journal={Psychoneuroendocrinology},
  year={1999},
  volume={24 6},
  pages={657-77}
}
Preliminary evidence from clinical studies indicates that treatment with estrogen augments cognitive function for women with Alzheimer's disease (AD). The neurobiology of estrogen, particularly its neuromodulatory and neuroprotective actions, provide a viable basis to support such cognition-enhancing effects. We conducted a placebo-controlled, double-blind, parallel-group design pilot clinical study to evaluate the cognitive and neuroendocrine response to estrogen administration for… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 61 extracted citations

Estrogen levels do not correlate with improvement in cognition.

Archives of neurology • 2003
View 8 Excerpts
Highly Influenced

Neuroprotection by estradiol.

View 2 Excerpts
Highly Influenced

The effects of ketamine on the mismatch negativity (MMN) in humans - A meta-analysis.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology • 2016

Similar Papers

Loading similar papers…